Mira Wollner

8 HaAliyah HaShniya Street, 3109601
Haifa, HA 31096, Israel

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 27 publications

Phase II study of 1st-line durvalumab and platinum-etoposide in advanced large-cell neuroendocrine lung carcinoma (aLCNEC).

Phase II study of 1st-line durvalumab and platinum-etoposide in advanced large-cell neuroendocrine lung carcinoma (aLCNEC).

Journal: Cancer immunology, immunotherapy : CII

Published: January 27, 2026

The association between geriatric assessment, muscle measures, and treatment-related toxicity in older adults with cancer: An Israeli prospective study.

The association between geriatric assessment, muscle measures, and treatment-related toxicity in older adults with cancer: An Israeli prospective study.

Journal: Journal of geriatric oncology

Published: May 12, 2022

Correction: Bar-Sela et al. Cannabis Consumption Used by Cancer Patients during Immunotherapy Correlates with Poor Clinical Outcome. Cancers 2020, 12, 2447.

Correction: Bar-Sela et al. Cannabis Consumption Used by Cancer Patients during Immunotherapy Correlates with Poor Clinical Outcome. Cancers 2020, 12, 2447.

Journal: Cancers

Published: March 22, 2022

dNLR-Based Score Predicting Overall Survival Benefit for The Addition of Platinum-Based Chemotherapy to Pembrolizumab in Advanced NSCLC With PD-L1 Tumor Proportion Score ≥50.

dNLR-Based Score Predicting Overall Survival Benefit for The Addition of Platinum-Based Chemotherapy to Pembrolizumab in Advanced NSCLC With PD-L1 Tumor Proportion Score ≥50.

Journal: Clinical lung cancer

Published: September 11, 2021

ALK Inhibitors or Chemotherapy for Third Line in ALK-positive NSCLC? Real-world Data.

ALK Inhibitors or Chemotherapy for Third Line in ALK-positive NSCLC? Real-world Data.

Journal: The oncologist

Published: June 12, 2021

Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data.

Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data.

Journal: Oncoimmunology

Published: February 08, 2021

Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of lung.

Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of lung.

Journal: Journal for immunotherapy of cancer

Published: December 29, 2020

Cannabis Consumption Used by Cancer Patients during Immunotherapy Correlates with Poor Clinical Outcome.

Cannabis Consumption Used by Cancer Patients during Immunotherapy Correlates with Poor Clinical Outcome.

Journal: Cancers

Published: July 12, 2020

Inflammatory changes in actinic keratoses associated with afatinib therapy.

Inflammatory changes in actinic keratoses associated with afatinib therapy.

Journal: Cutis

Published: May 01, 2020

Alternative nivolumab duration and scheduling in advanced nonsmall cell lung cancer: A real-world evidence.

Alternative nivolumab duration and scheduling in advanced nonsmall cell lung cancer: A real-world evidence.

Journal: International journal of cancer

Published: April 23, 2020

Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer: clinical and biomarker results from a phase I trial.

Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer: clinical and biomarker results from a phase I trial.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: October 13, 2019

Immune-related Neutropenia Following Treatment With Immune Checkpoint Inhibitors.

Immune-related Neutropenia Following Treatment With Immune Checkpoint Inhibitors.

Journal: Journal of immunotherapy (Hagerstown, Md. : 1997)

Published: September 10, 2019

Showing 1-12 of 27

Last Updated: 09/26/2026